Key result
miR-625-5p attenuated Ang II-induced cardiac hypertrophy by directly targeting and inhibiting the expression of STAT3 and CaMKII.
Why the study?
CaMKII is a key regulator of cardiac hypertrophy, but its regulatory mechanism remains largely unknown.
Population
In vivo and in vitro models of cardiac hypertrophy
Design
Preclinical in vivo and in vitro study
Authors
Loading...
Hypothesis-generating for miR-625-5p in hypertrophy; leaves open clinical translation from animal models.
miR-625-5p acts as a novel negative regulator of cardiac hypertrophy by targeting STAT3 and CaMKII, offering a potential molecular mechanism and therapeutic target.
Cai et al. (2019) studied Cardiac hypertrophy. miR-625-5p was evaluated on Cardiac hypertrophy. miR-625-5p attenuated Ang II-induced cardiac hypertrophy by directly targeting and inhibiting the expression of STAT3 and CaMKII.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: